Original Article / Оригинални рад

Marko Nenadović¹, Dejan Petrović D¹,², Jasna Trbojević-Stanković³,⁴

Beta-2 microglobulin removal with postdilution online hemodiafiltration –
comparison of three different dialysis membranes

Уклањање бета-2 микроглобулина постдилуционом online
хемодијафилтрацијом – процена ефикасности три различите дијализне
мембране

¹Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia;
²Kragujevac University Clinical Center, Clinic of Urology, Nephrology and Dialysis, Kragujevac, Serbia;
³University of Belgrade, Faculty of Medicine, Belgrade, Serbia;
⁴Dr. Dragiša Mišović – Dedine University Hospital Center, Belgrade, Serbia

Received: March 29, 2021
Accepted: May 25, 2021
Online First: May 31, 2021
DOI: https://doi.org/10.2298/SARH210329048N

*Accepted papers* are articles in press that have gone through due peer review process and have been
accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not
yet been copy-edited and/or formatted in the publication house style, and the text may be changed
before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they
can already be cited using the year of online publication and the DOI, as follows: the author’s last
name and initial of the first name, article title, journal title, online first publication month and year,
and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First,
February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be
removed and the final version will appear in the associated published volumes/issues of the journal.
The date the article was made available online first will be carried over.

*Correspondence to:*
Jasna TRBOJEVIĆ-STANKOVIĆ
Dr. Dragiša Mišović – Dedine University Hospital Center, 1 Heroja Milana Tepića, Belgrade 11040, Serbia
E-mail: jasna.trbojevic-stankovic@med.bg.ac.rs
Beta-2 microglobulin removal with postdilution online hemodiafiltration – comparison of three different dialysis membranes

**Summary**

**Introduction/Objective** Accumulation of middle molecular weight uremic toxins causes various complications in chronic hemodialysis (HD) patients. Postdilution online hemodiafiltration (OL-HDF) efficiently removes these molecules. This study aimed to assess the effectiveness of three different dialysis membranes in removing β2-microglobulin (β2m) within a single session of postdilution OL-HDF.

**Method** A prospective single-center study was carried out in 30 patients (23 males and 7 females, average age 54.87 ± 11.66 years, time on dialysis 4.95 ± 5.40 years) on maintenance HD. Each patient was followed for 3 consecutive weeks on OL-HDF with three different dialyzers: DiacapPro 19H, FX CorDiax 800, and Elisio 21H, randomly switched weekly. The reduction ratios (RR) of β2m and albumin were compared individually. Results were analyzed with the Kolmogorov-Smirnov test, ANOVA, and the Kruskal-Wallis test.

**Results** The average convective volume for all patients was 21.38 ± 2.97 L/session. β2m RR was 70.86 ± 6.87%, 74.69 ± 6.51%, and 70.04 ± 9.37% with Diacap Pro 19H, FX CorDiax 800 and Elisio 21H membrane respectively (p = 0.054). Albumin RR was 6.20 ± 2.12% with Diacap Pro 19H membrane, 6.01 ± 2.97% with FX CorDiax 800 membrane, and 6.46 ± 2.91% with Elisio 21H membrane (p = 0.812). Albumin loss was < 4.0g/dialysis treatment for all membranes.

**Conclusion** All investigated membranes effectively remove β2m in postdilution OL-HDF with a tolerable albumin loss. The highest β2m RR was determined for FX CorDiax 800 membrane, but with no statistically significant difference.

**Keywords:** uremic toxins; middle molecules; albumin; β2-microglobulin; dialyzer; hemodiafiltration

**Conclusion**

**Summary**

**Introduction/Objective** Накупљање уремијских токсина средње молекулске масе може узроковати бројне компликације код болесника леченх хроничним хемодијализама. Постдилуциони online хемодијафилтрацијом (OL-HDF) успешно уклања ове молекуле. Ово студије је имао за циљ да испита ефикасност три различитих дијализних мембрана у уклањању β2- микроглобулина (β2m) током појединачне сесије постдилуционе OL-HDF.

**Методе** Проспективном студијом је обухваћено 30 болесника (23 мушkaraca и 7 жена, просечна старост 54.87 ± 11.6 година, дужина дијализног лечења 4.95 ± 5.4 година) који су лечени постдилуционом OL-HDF-ом. Код свих испитаних је одређен индекс редукције β2m и албумина током једног третмана постдилуционом OL-HDF-ом. Код свих мембрана OL-HDF-ом суксесивном применом три дијализне мембране: DiacapPro 19H, FX CorDiax 800 и Elisio 21H. За статистичку анализу коришћен су Колмогоров-Смирновов тест, ANOVA и Крускал-Волисов тест.

**Резултати** Просечан укупни конвективни волумен је износио 21.38 ± 2.97 литара по сесији. Индекс редукције β2m износио је 70.86 ± 6.87% за мембрану DiacapPro 19H, 74.69 ± 6.51% за мембрану FX CorDiax 800, и 70.04 ± 9.37% за мембрану Elisio 21H (p = 0.054). Индекс редукције албумина је био 6.20 ± 2.12% за мембрану DiacapPro 19H, 6.01 ± 2.97% за мембрану FX CorDiax 800, и 6.46 ± 2.91% за мембрану Elisio 21H (p = 0.812). Губитак албумина у току појединачне дијализне сесије за све три дијализне мембране био је мањи од 4.0 g/4h.

**Закључак** Све испитане мембране ефикасно уклањају β2m применом OL-HDF уз безбедан губитак протеина. Највећи индекс редукције β2m уз најмањи губитак албумина остварен је применом мембране FX CorDiax 800.

**Кључне речи:** уремијски токсини; средњи молекули; албумин; β2- микроглобулин; дијализатор; хемодијафилтрација
INTRODUCTION

End-stage renal failure patients requiring maintenance hemodialysis (HD) exhibit significant retention of uremic toxins. Small, water-soluble molecules, weighing up to 500 Da and not bound to protein carriers are readily cleared with HD. However, larger and/or protein-bound uremic toxins are much more difficult to remove [1]. The "middle molecules", having a molecular weight from 500 to 60,000 Da, include several cytokines, adipokines, growth factors, and signaling proteins, such as interleukin-1 β, interleukin-6, interleukin-18, tumor necrosis factor α, β2-microglobulin (β2m), pentraxin-3, YKL-40, and leptin. They have diverse biological roles and are associated with chronic inflammation, cardiovascular disease, and other complications in HD patients [1]. Microinflammation, malnutrition, and oxidative stress are important non-traditional risk factors for the development of atherosclerosis and resistance to erythropoietin [1–5].

Conventional HD with high-flux membranes has very limited efficiency in removing larger middle molecules [1]. Modalities employing convective transport, such as online hemodiafiltration (OL-HDF), enable enhanced removal of large uremic toxins, thus achieving cardioprotective effect and improving outcomes for HD patients [6, 7, 8]. The efficiency of HDF in middle molecules removal depends on the overall convective volume (Vconv), which is related to vascular access blood flow (Qavf), effective blood flow (Qb), and membrane properties [6, 7, 8]. Contemporary HDF membranes have a high ultrafiltration coefficient (Kuf > 40 ml/h x mmHg), sieving coefficient for β2m >0.60, sieving coefficient for albumin <0.01 to prevent albumin loss over 4.0 g/4hr session, internal capillary diameter >200 µm and capillary density per surface area >11,000 allowing for dialysate flow (Qd) of 400–500 mL/min [6, 7, 8]. Vconv represents the sum of the substitution volume (Vsubs) and the net ultrafiltration volume (Vnuf) achieved to correct extracellular fluid overload. Vconv target should be ≥ 22 L per dialysis session to achieve a convection dose target [6, 7, 8].

In clinical practice, the efficiency of HDF treatment in clearing middle molecules is assessed by determining serum β2m levels before and after the procedure. β2m is a water-soluble polypeptide, made of 99 amino-acid residues, with a molecular weight of 11,815 Da. Its plasma levels increase with age in healthy individuals related to the physiological decrease in glomerular filtration rate over 50 years of age. The substance was first discovered some 50 years ago after being isolated from the urine of patients with tubular proteinuria due to
chronic cadmium poisoning [9]. Nevertheless, its significance in dialysis patients was only acknowledged 15 years later, when it was isolated as a major component of the amyloid substance in dialyzed individuals, predominantly targeting the cartilage of osteoarticular tissue [10]. The incidence of dialysis-related amyloidosis increases with patients’ age and longer dialysis vintage. The Japanese Society for Dialysis Therapy recommends achieving maximum predialysis serum $\beta_2 m$ concentration <30 mg/L, but preferably <25 mg/L to attenuate the development of this condition [11]. Also, $\beta_2 m$ seems to be significantly associated with mortality in maintenance HD patients [12].

This study aimed to assess the effectiveness of three different dialysis membranes in removing the middle molecule uremic toxin, $\beta_2 m$, with postdilution OL-HDF.

METHODS

This prospective, single-center study was carried out among 30 patients treated with maintenance postdilution OL-HDF in the Center for Nephrology and Dialysis, University Clinical Center Kragujevac. The study was conducted according to the Declaration of Helsinki and approved by the Ethics Committee of University Clinical Center Kragujevac (Decision No 01-20-765). All patients gave informed consent for participation.

All patients were receiving regular maintenance HDF program on Fresenius 5008S (Fresenius Medical Care, Germany), Gambro Artis (Gambro, Italy) and B.Braun Dialog+ (B.Braun Avitum, Germany) machines with controlled ultrafiltration, thrice weekly, with routine dialysis parameters: dialysis time 4 hours, dialysis buffer with bicarbonate, $Q_b$ range 257.00 ± 18.65 mL/min and dialysate flow (Qd) 500 mL/min. Blood flow and dialysate flow were not changed for any patient throughout the follow-up. The standard ultrapure dialysis fluid (bacterial count <0.1 CFU/L and endotoxin content <0.03 EU/mL) was used with dialysate temperature set at 37°C and sodium level of 140 mmol/L, potassium 2.0 mmol/L, magnesium 0.5 mmol/L, and calcium 1.25 mmol/L, 1.50 mmol/L or 1.75 mmol/L. The average $V_{conv}$ was 21.38 ± 2.97 L per dialysis session (Table 1). All patients were dialyzed through an arterio-venous fistula. The anticoagulation used was heparin sodium at an average dose of 4508.32 ± 541.92 IU per HDF session. Orders for anticoagulation type, dosage, and
administration regimen (bolus injection and continuous infusion) remained unchanged. The patients received treatment with different erythropoiesis-stimulating agents (epoetin-α, epoetin-β, darbepoetin-α). All patients were anuric with a diuresis of <50mL/day. Patients with an active infection, current bleeding issue, or on immunosuppressive therapy were not included in this investigation.

Each patient was followed for three consecutive weeks during which three different dialyzers – DiacapPro 19H (B. Braun Avitum, Germany), FX CorDix 800 (Fresenius Medical Care, Germany) and Elisio 21H (Nipro Corporation Japan), were switched on a weekly basis. The technical characteristics of each membrane are presented in Table 2 [13, 14, 15]. Thus, each patient underwent three consecutive treatments with each dialyzer in a randomly assigned sequence. Dialyzer setup and preparation involving a pre-rinsing were done per the clinic's standard operating procedure. All the dialyzers were pre-rinsed in the same manner.

Blood was collected on mid-week dialysis before and after the treatment. Serum β2m and albumin concentrations were determined by the turbidimetric method on the Beckman Coulter AU680 chemistry analyzer. The reference range for β2m in healthy adults with this method is 0.97 – 1.84 mg/L and the optimum target predialysis β2m serum level in dialyzed patients is <25 mg/L. The serum albumin reference range is 35–57 g/L. β2m reduction ratio (RR) was calculated from the following equation: RRβ2m (%) = [1 - (Cpost/Cpre)] × 100; where Cpre stands for β2m level before and Cpost for β2m level after the predilution OL- HDF session [16]. Serum albumin concentration after OL- HDF session was calculated from the following formula: Albuminpost = Calb post/[1 + [(UF)/0.2 × (BWpre – UF)]], where C_alb is measured serum albumin concentration (g/L), UF is net ultrafiltration achieved during the particular dialysis session (L/4hr), and BWpre is measured body weight before dialysis (kg) [16]. Albumin RR was determined from the equation: RRAlb = [1-(Cpost/Cpre)] x 100, where C_pre is serum albumin concentration before dialysis (g/L) and C_post – serum albumin concentration after dialysis (g/L), [16].

Ferritin and C-reactive protein (CRP) serum levels were determined on the Beckman Coulter AU680 apparatus. The reference range for ferritin in maintenance HD patients is 100–500 ng/mL. CRP was expressed as an average from two consecutive monthly

DOI: https://doi.org/10.2298/SARH210329048N Copyright © Serbian Medical Society
measurements with a normal value being ≤ 5 mg/L and level >5 mg/L signifying the presence of microinflammation. Intact parathyroid hormone (iPTH) in serum was determined with immunoradiometric assay (IRMA) on WALLAC WIZARD 1470 gamma counter. The normal range for iPTH is 11.8–64.5 pg/mL, and the upper limit for maintenance HD patients is 675 pg/mL [17]. Prealbumin and transferrin levels were determined with an immunoturbidimetric method on the Abbott Architect machine. The normal results for a prealbumin blood test in hemodialyzed adults are ≥ 0.30 g/L.

Normalized protein catabolic rate (nPCR) was calculated from the formula: nPCR = (PCR x 0.58)/Vd, where PCR is protein catabolic rate, Vd is body fluid volume. PCR was determined from the equation: PCR = [(9.35 x G) + (0.29 x Vd)], where G stands for an interdialytic rise in urea, which is established from the formula G=[(C1-C2)/Id] x Vd, where C1 and C2 denote pre- and post-dialysis urea concentrations (mmol/L) and Id – the time between the two dialyzes (h). Body fluid volume is calculated as Vd = 0.58 x DW, where DW is dry body mass, i.e. patients’ body mass after stable dialysis (kg), [18].

Interdialytic weight gain (IDWG) was calculated as the patients' weight at the beginning of each HD session minus the weight after the previous HD session, divided by the nephrologists’ determined dry weight (%).

Dialysis adequacy was assessed based on the single pool Kt/V index calculated according to the Daugirdas second-generation formula: Kt/Vsp = -ln(C2/C1 – 0.008 x T) + (4 – 3.5 x C2/C1) x UF/W, where C1 and C2 are pre-post dialysis urea levels (mmol/L), T is dialysis duration (h), UF – ultrafiltrate removed (L) and W body weight after HD (kg). According to the K/DOQI guidelines, the target Kt/Vsp is ≥ 1.2 [18].

The urea reduction ratio (URR) was calculated from the formula: URR = (1-R) x 100%; where R is the difference between pre- and post-dialysis urea serum concentration. URR target range for adequate dialysis is 65–70% [18].

Arterio-venous fistula blood flow (Qavf) was measured with Color Doppler ultrasound examination on Logic P5 machine, with a 7.5 MHz probe. The reference range for adequate blood flow is 500–1,000 mL/min.
Data were analyzed by Kolmogorov–Smirnov test, ANOVA, and Kruskal–Wallis test, using the SPSS Statistic for Windows, Version 25.0 (IBM Corp., Armonk, NY, USA) for statistical analysis.

RESULTS

The study population consisted of 23 males and 7 females with an average age of 54.87 ± 11.66 years, an average time on dialysis of 4.95 ± 5.40 years, average body mass index of 23.49 ± 3.75 kg/m², and average dialysis adequacy index (spKt/V) of 1.41 ± 0.25 (Table 3). The etiology of end-stage renal disease was nephroangiosclerosis in 11 patients (36.66%), chronic glomerulonephritis in 7 patients (23.32%), polycystic kidney disease in 4 patients (13.34%), and diabetic kidney disease, obstructive nephropathy, and unknown chronic nephropathy in 1 patient each. The comorbidities included hypertension (21 patients; 70.00%), hypertensive cardiomyopathy (7 patients; 23.32%), dilatative cardiomyopathy (1 patient; 3.34%) and complications of diabetes mellitus (1 patient; 3.34%). Mean serum indicators of anemia, iron status, micorinflammation, malnutrition, and secondary hyperparathyroidism are presented in Table 4. Patients had well-controlled blood pressure and did not exceed the recommended values of IDWG.

Twenty-one patients (70.00%) had predialysis serum β2m level < 30 mg/L. Among them, 11 patients (36.67%) had predialysis serum β2m level <25 mg/L. The average RR of β2m was 70.86 ± 6.87% with Diacap Pro 19H membrane, 74.69 ± 6.51%, with FX CorDiax 800 membrane, and 70.04 ± 9.37% with Elisio 21H membrane. No statistically significant difference (p>0.05) was observed between these values (Table 5).

All patients had post-dialysis serum albumin concentration >35 g/L. The average decrease in serum albumin level after OL- HDF with Diacap Pro 19H, FX CorDiax 800, and Elisio 21H membranes was 2.50 ± 0.92 g/L, 2.40 ± 1.28 g/L, and 2.60 ± 1.20 g/L respectively. RR of albumin with the same membranes was 6.20 ± 2.12%, 6.01 ± 2.97%, and 6.46 ± 2.91% respectively. No statistically significant difference (p > 0.05) was observed in neither of these parameters between different dialyzers (Table 5).
DISCUSSION

Cardiovascular diseases are the leading cause of death in patients on maintenance HD. Uremic toxins, altered endothelial function, chronic microinflammation, malnutrition, oxidative stress, resistance to erythropoietin, and anemia are the major non-traditional risk factors for the development of cardiovascular complications in this population [19, 20]. Early detection and optimal control of these issues seem to play a key role in preventing cardiovascular co-morbidity in HD patients [21]. In recent years, direct cardiotoxicity of uremic toxins has been increasingly demonstrated, while a reduction in middle molecule retention appears to be independently associated with decreased risk of mortality [22].

β2m is a prototype of middle molecules, commonly used as a representative marker of this group of molecules retention and removal. Its concentration notably increases in end-stage renal failure and may cause the development of dialysis-related amyloidosis [23, 24]. The target β2m predialysis level of <30mg/L was met in 70% of our study population, while 36.67% even had predialysis β2m level < 25ml/L [11, 23–26]. The highest β2m removal rate in our study population was achieved with FX CorDiax 800 dialyzer, even though the difference was not statistically significant. This advantageous performance can be explained by the FX CorDiax membrane characteristics which have a higher sieving coefficient compared to the other investigated membranes.

Previous studies have demonstrated that the average β2m removal rate ranges from 50–60% with regular high-flux HD, to 70% with medium cut-off membranes, to 80–85% with high volume (Vconv > 22 L / dialysis session) post-dilution OL-HDF [23–26]. The somewhat lower β2m reduction ratio achieved with post-dilution OL-HDF in our study population, ranging from 70.04–74.69%, can be explained by lower than average Vconv and Qb in our study population (Table 1). High Vconv is the key factor for efficient removal of middle molecules with high volume online post-dilution and patients with Vconv <22 L per dialysis session have significantly lower Qb and higher filtration fraction (FF) compared to patients with higher Vconv. Nevertheless, in clinical practice, Vconv ≥ 22 L per session is attainable in only around 75% of patients. In our study population, 50% of the patients achieved Vconv ≥ 22 L, while an overall 66.67% had Vconv ≥ 20 L per dialysis session. Optimization of
overall $V_{\text{conv}}$ depends on patient-related factors, such as hematocrit and serum total protein level, as well as on dialysis-related determinants, including $Q_b$, type of dialysis machine, and dialysis session length [27, 28]. The target $Q_b$ should be $\geq 350$ ml/min and it depends on $Q_{\text{avf}}$ and the diameter of dialysis needles. A mature fistula should have a blood flow rate greater than 600 mL/min and some of the patients in our study group failed to fulfill this criterion due to poorly functioning fistulas, thus affecting the possibility to achieve target $Q_b$ [28]. High hematocrit and high total serum protein may increase filtration fraction and decrease overall $V_{\text{conv}}$, however, this was not the case in our study population. Besides these factors, achieving and maintaining target $V_{\text{conv}}$ also requires continuous education and training of medical staff [28].

The lowest albumin loss during the HDF session in our study group was demonstrated with FX CorDiax 80 dialyzer. The advertised membrane characteristics for this dialyzer present a lower sieving coefficient for albumin compared to Elisio 21 dialyzer (Table 2). Nevertheless, all patients in this study had albumin reduction ratio $< 11\%$, accounting for a tolerable albumin loss of $< 3.5$ g per 4-hour dialysis session. Furthermore, all patients had post-dialysis serum albumin level $>35$ g/L. Even though HDF provides a better clearance of middle molecules than conventional dialysis thus possibly improving survival, OL-HDF can lead to an increase in albumin loss across the dialyzer, especially with high permeability membrane and high convective volume, which can eventually lead to malnutrition [29, 30]. It is therefore important to note that none of the patients in our study developed hypoalbuminemia.

**CONCLUSION**

All investigated membranes effectively remove middle-molecular-weight uremic toxins with an acceptable albumin loss. The highest removal rate of $\beta_2$m and lowest albumin loss was achieved with FX CorDiax 800 dialyzer.
ACKNOWLEDGMENT

Authors would like to express their deepest gratitude to the Ministry of Education, Science and Technological Development of the Republic of Serbia for the Grant №175014 and also to the Faculty of the Medical Sciences, University of Kragujevac, for their Junior Project grants №02/19 and №22/20 from which the funds were used as one of the sources to financially support this paper.

Conflict of interest: None declared.
REFERENCES

1. Wolley MJ, Hutchison CA. Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant 2018; 33(Suppl 3): 6–11. DOI: 10.1093/ndt/gfy179. PMID: 30281131.

2. Kaesler N, Babler A, Floege J, Kramann R. Cardiac Remodeling in Chronic Kidney Disease. Toxins 2020; 12(3): 161. DOI: 10.3390/toxins12030161. PMID: 32150864.

3. Mair RD, Sirich TL, Meyer TW. Uremic Toxin Clearance and Cardiovascular Toxicities. Toxins 2018; 10(6): 226. DOI: 10.3390/toxins1006226. PMID: 29865226.

4. Fujii H, Goto S, Fukagawa M. Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction. Toxins 2018; 10(5): 202. DOI: 10.3390/toxins10050202. PMID: 29772660.

5. Sahathevan S, Khor BH, Ng HM, Gafor AHA, Daad ZAM, Mafra D, et al. Understanding Development of Malnutrition in Hemodialysis Patients: A Narrative Review. Nutrients 2020; 12(10): 3147. DOI: 10.3390/nu12103147. PMID: 33058473.

6. Guedes M, Dambiski AC, Canhada S, Barra ABL, Poli-de-Figueiredo CE, Cuvello Neto AL; HDFIT Study Investigators. Achieving high convective volume in hemodiafiltration: Lessons learned after successful implementation in the HDFIT trial. Hemodial Int. 2021; 25(1): 50–59. DOI: 10.1111/hdi.12891. PMID: 33058473.

7. Perez-Garcia R, Alcazar R. The dialyzer in the year 2017: Much more than a membrane. Nefrologia 2018; 38(1): 4–7. DOI: 10.1016/j.nefro.2018.01.006. PMID: 29122381.

8. De Roij van Zuijdewijn CLM, Chapdelaine I, Nube MJ, Konings CIAM, et al. Achieving high concentration volumes in postdilution online hemodiafiltration: a prospective multicenter study. Clin Kidney J 2017; 10(6): 804–12. DOI: 10.1093/ckj/sfw140. PMID: 29225810.

9. Berggard I, Bearn AG. Isolation and properties of a low molecular weight beta-2-microglobulin occurring in human biological fluids. J Biol Chem 1968; 243:4095–4103. PMID: 4175239.

10. Shirama T, Skinner M, Cohen AS, Gejyo F, Arakawa M, Suzuki M, Hirasa Y. Histochemical and immunohistochemical characterization of amyloid associated with chronic hemodialysis as β2m. Lab Invest 1985; 53: 705–709. PMID: 2415776.

11. Waterabe Y, Kawanishi H, Suzuki K, Nakai S, Tsuchida K, Tabei K, et al. Japanese Society for Dialysis Therapy Clinical Guideline for “Maintenance Hemodialysis: Hemodialysis Prescription”. Ther Apher Dial 2015;19 (Suppl 1): 67–92. DOI: 10.1111/1744-9987. PMID: 25817933.

12. Kanda E, Muenz D, Bieber B, Cases A, Locatelli F, Port FK, et al. Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study. Clin Kidney J. 2020; 14(S): 1436–1442. DOI: 10.1093/ckj/sfaa155. PMID: 33959272.

13. Misra M, Moore H. A clinical study comparing the basic performance and blood compatibility characteristics of Nipro ELISIO-HG, Gambro Polyflux Revaclear and Fresenius Optiflux dialyzers. Hemodialysis Int 2018; 22(Suppl 2): 15–23. DOI: 10.1111/ndi.12699. PMID: 30358917.

14. Maduell F, Ojeda R, Belmar L, Manguia P, Sango C, Martinez-Diaz AI, Arias-Guillen M, et al. Evaluation of the dialyzer inner diameter in online haemodiafiltration. Nefrologia 2018; 38(1): 34–40. DOI: 10.1016/j.nefro.2017.03.013. PMID: 29325671.

15. BBraun Product Catalog version 04/2017. Diacap Pro high flux: performance data. Bbraun Avitum AG, Germany: www.bbraun-dialysis.com.

16. Tiong MK, Krishnasamy R, Smith ER, Hutchison CA, Ryan EG, Pascoe EM, et al. Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodial Int. 2021 (online, ahead of print). DOI: 10.1111/ndi.12924. PMID: 33779046.

17. KDOI 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017; 7(1): 1–59. DOI: 10.1016/S2157-1716(17)30005-9. PMID: 30675420.

18. National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis 2015; 66(5): 884–930. DOI: 10.1053/j.ajkd.2015.07.015. PMID: 26498416.

19. Jačović S, Jovanović M, Hamzagić N, Pavlović R, Petrović D. Erythropoietin Resistance in Hemodialysis Patients. Acta Fac Med Naiss 2019; 36(1): 5–14. DOI: 10.2478/afmnai-2019-0001.
20. Antić S, Draginić N, Jovanović M, Nikolić T, Jeremić N, Živković V, Srejović I, Petrović D, Jakovljević V. The relation between oxidative stress and carotid artery atherosclerosis in hemodialysis patients. Ser J Exp Clin Res 2019; DOI: 10.2478/sjcr-2019-0052.
21. Antić S, Draginić N, Pilčević D, Živković V, Srejović I, Jeremić N, Petrović D, Jakovljević V. The influence of vitamin E coated dialysis membrane on oxidative stress during the single session of on-line hemodiafiltration. Vojnosanit Pregl 2019; DOI: 10.2298/VSP190730097A.
22. Lekawanvijit S. Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome. Toxins (Basel). 2018;10(9):352. DOI: 10.3390/toxins10090352. PMID: 30200452.
23. Neri L, Gurevich K, Zarya Y, Plavinskii S, Bellocchio F, et al Practice Patterns and Outcomes of Online Hemodiafiltration: A Real-World Evidence Study in a Russian Dialysis Network. Blood Purif. 2020:1–10. DOI: 10.1159/000510551. PMID: 32966994.
24. Blankestijn PJ, Grooteman MP, Nube MJ, Bots ML. Clinical evidence on haemodiafiltration. Nephrol Dial Transplant 2018; 33(Suppl 3): 53–8. DOI: 10.1093/ndt/gfy218. PMID: 30281128.
25. Masacane I, Sakurai K. Current approaches to middle molecule removal: room for innovation. Nephrol Dial Transplant 2018; 33(Suppl 3): 12–21. DOI: 10.1093/ndt/gfy224. PMID: 30281129.
26. Magnani S, Atti M. Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives. Toxins (Basel). 2021;13(4):246. DOI: 10.3390/toxins13040246. PMID: 33808345.
27. Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol 2018; 14(6): 394-410. DOI: 10.1038/s41581-018-0002-x. PMID: 29730670.
28. Canaud B, Vienken J, Ash S, Ward R. Hemodiafiltration to Address Unmet Medical Needs ESKD Patients. Clin J Am Soc Nephrol 2018; 13(9): 1435–43. DOI: 10.2215/CJN.12631117. PMID: 29511057.
29. Maduell F, Rodas L, Broseta JJ, Gomez M, Xipell M, Guilleñ E, et al. Medium Cut-Off Dialyzer versus Eight Hemodiafiltration Dialyzers: Comparison Using a Global Removal Score. Blood Purif 2019; 48(2): 167–74. DOI: 10.1159/000499759. PMID: 30943486.
30. Cuvelier, C., Tintillier, M., Migali, G. et al. Albumin losses during hemodiafiltration: all dialyzers are not created equal - a case report. BMC Nephrol 2019; 20: 392. DOI: 10.1186/s12882-019-1567-8. PMID: 31660886.
Table 1. Dialysis-related parameters in the investigated population

| Variable     | Mean ± SD      |
|--------------|---------------|
| Qnuf (ml/min)| 11.74 ± 3.90  |
| Qsubs (ml/min)| 80.64 ± 14.20|
| Qconv (ml/min)| 92.37 ± 13.39|
| Vsubs (l)    | 18.58 ± 3.20  |
| Vconv (l)    | 21.38 ± 2.97  |
| FF (%)       | 36.00 ± 5.00  |
| Qb (mL/min)  | 257.00 ± 18.65|

Qnuf – net ultrafiltration rate; Qsubs – substitution flow rate; Qconv – convective flow rate; Vsubs – substitution volume; Vconv – overall convective volume; FF – filtration fraction; Qb – effective blood flow
Table 2. Characteristics of investigated membranes

| Characteristic                        | Diacap Pro 19H | FX CorDix 800 | Elisio 21H |
|--------------------------------------|----------------|---------------|------------|
| Composition                          | α-polysulfone pro | Helixone plus | Polyethersulfone |
| Surface (m²)                         | 1.9            | 2.0           | 2.1        |
| Kuf (ml/h/mmHg)                      | 97             | 62            | 76         |
| Capillary wall thickness (µm)        | 37             | 35            | 40         |
| Internal capillary diameter (µm)     | 200            | 210           | 200        |
| β₂-microglobulin SC                  | 0.700          | 0.900         | 0.800      |
| Albumin SC                           | < 0.001        | < 0.001       | 0.002      |
| Sterilization method                 | Gamma rays     | Steam         | Gamma rays |
| Manufacturer                         | B. Braun Avitum AG, Germany | Fresenius Medical Care, Germany | Nipro Corporation, Japan |

Kuf — ultrafiltration coefficient, SC — sieving coefficient
Table 3. General patients’ data

| General patients’ data                                      | Mean ± SD         |
|-------------------------------------------------------------|-------------------|
| Number                                                      | 30                |
| Sex (M/F, %)                                                | 23/7 (76.66/23.34)|
| Age (years)                                                 | 54.87 ± 11.66     |
| Time on dialysis (years)                                    | 4.95 ± 5.40       |
| Body mass index (kg/m$^2$)                                  | 23.49 ± 3.75      |
| Systolic arterial blood pressure (mmHg)                     | 128 ± 8.72        |
| Diastolic arterial blood pressure (mmHg)                    | 77.32 ± 5.12      |
| Mean arterial blood pressure (mmHg)                         | 94.22 ± 5.3       |
| Dry body weight (kg)                                        | 71.82 ± 12.54     |
| Interdialytic weight gain (kg)                              | 2.35 ± 0.94       |
| IDWG as a percentage of dry body weight (%)                 | 3.44 ± 1.58       |
| Ultrafiltration rate (mL/h)                                 | 587.5 ± 235.2     |
| Ultrafiltration rate per body mass (ml/kg/h)                | 8.57 ± 3.92       |
| Vascular access blood flow rate (ml/min)                    | 936 ± 460.9       |
| Single pool Kt/V                                            | 1.41 ± 0.25       |
| Urea reduction ratio (%)                                    | 69.41 ± 7.06      |

IDWG – interdialytic weight gain
Table 4. Laboratory parameters in the investigated population

| Laboratory parameters | Mean ± SD            |
|-----------------------|----------------------|
| Hemoglobin (g/l)      | 101.2 ± 7.06         |
| Hematocrit (%)        | 30.45 ± 1.78         |
| Iron (µmol/l)         | 11.2 ± 5.5           |
| TSAT (%)              | 33.52 ± 15.2         |
| Ferritin (ng/ml)      | 568.42 ± 267.85      |
| Transferrin (g/l)     | 1.6 ± 0.4            |
| iPTH (pg/ml)          | 220.22 ± 189.45      |
| Total protein (g/l)   | 66.57 ± 3.02         |
| Albumin (g/l)         | 39.77 ± 2.64         |
| Prealbumin (g/l)      | 0.34 ± 0.09          |
| Uric acid (µmol/l)    | 368 ± 68.72          |
| C-reactive protein (mg/l) | 4.57 ± 5.48     |
| nPCR (g/kg/24h)       | 2 ± 0.6              |

TSAT – transferrin saturation; nPCR – normalized protein catabolic rate; iPTH – intact parathyroid hormone
Table 5. β2-microglobulin reduction rate, serum albumin decrease and albumin reduction rate within a single post-dilution OL-HDF session

| Variable               | Membrane type      | p     |
|------------------------|--------------------|-------|
| RR-β2M (%)             | Diacap Pro 19H     | 70.86 ± 6.87 | 0.054 |
|                        | FX CorDiax 800     | 74.69 ± 6.51 |       |
|                        | Elisio 21H         | 70.04 ± 9.37 |       |
| Δ sAlbumin (g/L)       | Diacap Pro 19H     | 2.5 ± 0.92  | 0.746 |
|                        | FX CorDiax 800     | 2.4 ± 1.28  |       |
|                        | Elisio 21H         | 2.60 ± 1.2  |       |
| RR-Albumin (%)         | Diacap Pro 19H     | 6.2 ± 2.12  | 0.812 |
|                        | FX CorDiax 800     | 6.01 ± 2.97 |       |
|                        | Elisio 21H         | 6.46 ± 2.91 |       |

RR – reduction rate; Δ – difference between pre-and post-dialysis levels; s – serum